Dow Jones
38.105,69 +202,40 (+0,53%) Nasdaq
15.755,40 +149,92 (+0,96%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0720 +0,0002 (+0,02%) Bitcoin EUR
55.062,49 +2.025,36 (+3,82%) CMC Crypto 200
1.272,02 +1,28 (+0,10%)
Lixte Biotechnology Holdings, Inc. (8640.F)
| Chiusura precedente | 6,1000 |
| Aperto | N/D |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | N/D - N/D |
| Intervallo di 52 settimane | 4,6000 - 8,5500 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 0 |
| Beta (5 anni mensile) | -0,29 |
| Rapporto PE (ttm) | -0,00 |
| EPS (ttm) | -3,3900 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireLIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in
- GlobeNewswire
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D. Dr. Kovach, 87, founded the Company in 2005 and held a distinguished medical and scientific career that focused on the causation and treatment of cancer. Dr. Kovach serve
GlobeNewswireLIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology Holdings Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, anno
